{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:48:16Z","timestamp":1792788496270,"version":"4.5.0"},"reference-count":144,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T00:00:00Z","timestamp":1728518400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To assess the efficacy and safety of iguratimod (IGU) in the treatment of inflammatory arthritis and degenerative arthritis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Initially, randomized controlled trials (RCTs) on using IGU in treating inflammatory arthritis and degenerative arthritis were systematically gathered from various databases up to February 2024. Subsequently, two researchers independently screened the literature, extracted data, assessed the risk of bias in included studies, and conducted a meta-analysis using RevMan 5.4 software.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Fifty-four RCTs involving three inflammatory arthritis were included, including ankylosing spondylitis (AS), osteoarthritis (OA), and rheumatoid arthritis (RA). For AS, the meta-analysis results showed that IGU may decrease BASDAI (SMD \u22121.68 [\u22122.32, \u22121.03],\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.00001) and BASFI (WMD \u22121.29 [\u22121.47, \u22121.11],\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.00001); IGU may also decrease inflammatory factor [ESR: (WMD \u221210.33 [\u221214.96, \u22125.70],\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.0001); CRP: (WMD \u221210.11 [\u221214.55, \u22125.66],\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.00001); TNF-\u03b1: (WMD \u22126.22 [\u22127.97, \u22124.47],\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.00001)]. For OA, the meta-analysis results showed that IGU may decrease VAS (WMD \u22122.20 [\u22122.38, \u22122.01],\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.00001) and WOMAC (WMD \u22127.27 [\u221212.31, \u22122.24],\n                      <jats:italic>P<\/jats:italic>\n                      = 0.005); IGU may also decrease IL-6 (WMD \u22128.72 [\u221210.00, \u22127.45],\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.00001). For RA, the meta-analysis results showed that IGU may improve RA remission rate [ACR20: (RR 1.18 [1.02, 1.35],\n                      <jats:italic>P<\/jats:italic>\n                      = 0.02); ACR50: (RR 1.32 [1.05, 1.64],\n                      <jats:italic>P<\/jats:italic>\n                      = 0.02); ACR70: (RR 1.44 [1.02, 2.04],\n                      <jats:italic>P<\/jats:italic>\n                      = 0.04)] and decrease DAS28 (WMD \u22120.92 [\u22121.20, \u22120.63],\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.00001); IGU may also decrease inflammatory factors [CRP: (SMD \u22121.36 [\u22121.75, \u22120.96],\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.00001); ESR: (WMD \u22129.09 [\u221211.80, \u22126.38],\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.00001); RF: (SMD \u22121.21 [\u22121.69, \u22120.73],\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.00001)]. Regarding safety, adding IGU will not increase the incidence of adverse events.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>IGU might emerge as a promising and secure therapeutic modality for addressing AS, OA, and RA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic Review Registration<\/jats:title>\n                    <jats:p>Identifier PROSPERO: CRD42021289249<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2024.1440584","type":"journal-article","created":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T03:19:41Z","timestamp":1728530381000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["A systematic review and meta-analysis of the efficacy and safety of iguratimod in the treatment of inflammatory arthritis and degenerative arthritis"],"prefix":"10.3389","volume":"15","author":[{"given":"Zhiyong","family":"Long","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liuting","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kailin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junpeng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanfang","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles C.","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anqi","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wensa","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingyun","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,10,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"44","DOI":"10.3969\/j.issn.1674-4985.2021.02.011","article-title":"Observation on the clinical effect of iguratimod in the treatment of axial spondyloarthritis","volume":"18","author":"Bai","year":"2021","journal-title":"Chin. Med. Innov."},{"key":"B3","volume-title":"The effect of Iguratimod combined with methotrexate on serum VEGF levels in patients with rheumatoid arthritis and evaluation of the efficacy[D]","author":"Bi","year":"2019"},{"key":"B4","doi-asserted-by":"publisher","first-page":"e070856","DOI":"10.1136\/bmj-2022-070856","article-title":"Therapeutic advances in rheumatoid arthritis","volume":"384","author":"Brown","year":"2024","journal-title":"BMJ"},{"key":"B5","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1016\/S0140-6736(17)31491-5","article-title":"Novel treatment strategies in rheumatoid arthritis","volume":"389","author":"Burmester","year":"2017","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","first-page":"110913","DOI":"10.1016\/j.intimp.2023.110913","article-title":"A novel drug combination of Tofacitinib and Iguratimod alleviates rheumatoid arthritis and secondary osteoporosis","volume":"124","author":"Chen","year":"2023","journal-title":"Int. Immunopharmacol."},{"key":"B7","first-page":"552","article-title":"Effects of Iguratimod combined with methotrexate on serum inflammatory factors and bone metabolism in patients with rheumatoid arthritis","volume":"28","author":"Chen","year":"2018","journal-title":"Zhejiang J. Integr. Traditional Chin. West. Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/01.JAA.0000979536.73946.98","article-title":"Treatment options for symptomatic knee osteoarthritis in adults","volume":"36","author":"Clark","year":"2023","journal-title":"JAAPA"},{"key":"B9","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1186\/s13018-021-02530-2","article-title":"T-614 attenuates knee osteoarthritis via regulating Wnt\/\u03b2-catenin signaling pathway","volume":"16","author":"Cong","year":"2021","journal-title":"J. Orthop. Surg. Res."},{"key":"B10","article-title":"Chapter 16: special topics in statistics","volume-title":"Cochrane Handbook for systematic reviews of interventions","author":"Deeks","year":""},{"key":"B11","article-title":"Chapter 8: assessing risk of bias in included studies","volume-title":"Cochrane Handbook or systematic reviews of interventions","author":"Deeks","year":""},{"key":"B12","article-title":"Chapter 9: analyzing data and undertaking meta-analyses","volume-title":"Cochrane Handbook for systematic reviews of interventions","author":"Deeks","year":""},{"key":"B13","volume-title":"Deng JX the effect of Iguratimod on the proliferation and migration of fibroblast-like synovial cells in rheumatoid arthritis and the clinical observation","year":"2017"},{"key":"B14","doi-asserted-by":"publisher","first-page":"5684293","DOI":"10.1155\/2022\/5684293","article-title":"Influence of iguratimod on bone metabolism in patients with rheumatoid arthritis: a meta-analysis","volume":"2022","author":"Deng","year":"2022","journal-title":"Int. J. Clin. Pract."},{"key":"B15","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1016\/S0140-6736(23)01525-8","article-title":"Rheumatoid arthritis","volume":"402","author":"Di Matteo","year":"2023","journal-title":"Lancet"},{"key":"B17","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.intimp.2012.03.003","article-title":"T-614 alters the production of matrix metalloproteinases (MMP-1 and MMP-3) and inhibits the migratory expansion of rheumatoid synovial fibroblasts, in vitro","volume":"13","author":"Du","year":"2012","journal-title":"Int. Immunopharmacol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1007\/s10067-015-2999-6","article-title":"Efficacy and safety evaluation of a combination of iguratimod and methotrexate therapy for active rheumatoid arthritis patients: a randomized controlled trial","volume":"34","author":"Duan","year":"2015","journal-title":"Clin. Rheumatol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"81","DOI":"10.15887\/j.cnki.13-1389\/r.2020.33.031","article-title":"The clinical efficacy of iguratimod combined with methotrexate in the treatment of rheumatoid arthritis","volume":"13","author":"Fan","year":"2020","journal-title":"J. Clin. Ration. Use"},{"key":"B39","doi-asserted-by":"publisher","first-page":"97","DOI":"10.3969\/j.issn.1006-7108.2019.01.018","article-title":"Effects of Iguratimod on peripheral blood osteoclast differentiation and osteoclast-related gene expression in rheumatoid arthritis","volume":"25","author":"Feng","year":"2019","journal-title":"Chin. J. Osteoporos."},{"key":"B20","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1056\/NEJMra2103726","article-title":"Rheumatoid arthritis - common origins, divergent mechanisms","volume":"388","author":"Gravallese","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"B21","first-page":"138","article-title":"The clinical efficacy of iguratimod combined with methotrexate in the treatment of early rheumatoid arthritis","volume":"26","author":"Gu","year":"2020","journal-title":"Contemp. Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.13748\/j.cnki.issn1007-7693.2014.10.029","article-title":"Observation on the short-term clinical effect of iguratimod on rheumatoid arthritis complicated with chronic interstitial pneumonia","volume":"31","author":"Guifeng","year":"2014","journal-title":"China Mod. Appl. Pharm."},{"key":"B23","doi-asserted-by":"publisher","first-page":"e225","DOI":"10.1016\/S2665-9913(23)00060-7","article-title":"The influence of sex hormones on musculoskeletal pain and osteoarthritis","volume":"5","author":"Gulati","year":"2023","journal-title":"Lancet Rheumatol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"151","DOI":"10.3969\/j.issn.1673-8705.2018.02.003","article-title":"Protective effects of Iguratimod on lung tissue of mice with pulmonary fibrosis","volume":"12","author":"Han","year":"2018","journal-title":"Chin. J. Clin. Immun. Allergy"},{"key":"B25","first-page":"1749","article-title":"104 cases of active elderly rheumatoid arthritis treated with Iguratimod or methotrexate combined with leflunomide","volume":"32","author":"Han","year":"2023","journal-title":"Chin. J. New Drugs"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10165-006-0542-y","article-title":"Efficacy and safety of iguratimod compared with placebo and salazosulfapyridine in active rheumatoid arthritis: a controlled, multicenter, double-blind, parallel-group study","volume":"17","author":"Hara","year":"2007","journal-title":"Mod. Rheumatol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"410","DOI":"10.3109\/14397595.2013.843756","article-title":"Safety and efficacy of combination therapy of iguratimod with methotrexate for patients with active rheumatoid arthritis with an inadequate response to methotrexate: an open-label extension of a randomized, double-blind, placebo-controlled trial","volume":"24","author":"Hara","year":"2014","journal-title":"Mod. Rheumatol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1002\/med.22022","article-title":"Natural products as IL-6 inhibitors for inflammatory diseases: synthetic and SAR perspective","volume":"44","author":"Harmalkar","year":"2024","journal-title":"Med. Res. Rev."},{"key":"B29","first-page":"152","article-title":"Clinical observation of iguratimod in the treatment of rheumatoid arthritis complicated with interstitial lung disease","volume":"19","author":"He","year":"2015","journal-title":"J. Pract. Clin. Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"16468","DOI":"10.3390\/ijms242216468","article-title":"Inflammatory and metabolic signaling interfaces of the hypertrophic and senescent chondrocyte phenotypes associated with osteoarthritis","volume":"24","author":"Horv\u00e1th","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.23736\/S0026-4806.20.07227-4","article-title":"Iguratimod alleviates systemic lupus erythematosus-induced renal injury by inhibiting IL-33\/ST2 pathway","author":"Hou","year":"2021","journal-title":"Minerva Med."},{"key":"B32","volume-title":"Observation on the efficacy and safety of Iguratimod in the treatment of rheumatoid arthritis","author":"Hu","year":"2014"},{"key":"B33","doi-asserted-by":"publisher","first-page":"111282","DOI":"10.1016\/j.intimp.2023.111282","article-title":"SLAMF3 promotes Th17 differentiation and is reversed by iguratimod through JAK1\/STAT3 pathway in primary Sj\u00f6gren's syndrome","volume":"126","author":"Hu","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"92","DOI":"10.3969\/j.issn.1007-614x.2018.13.052","article-title":"Observation on the short-term curative effect of iguratimod in the treatment of ankylosing spondylitis","volume":"34","author":"Huang","year":"2018","journal-title":"Chin. Community Physician"},{"key":"B36","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1007\/s10165-012-0724-8","article-title":"Concomitant iguratimod therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate: a randomized, double-blind, placebo-controlled trial","volume":"23","author":"Ishiguro","year":"2013","journal-title":"Mod. Rheumatol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1080\/14397595.2018.1481565","article-title":"Iguratimod, a synthetic disease modifying anti-rheumatic drug inhibiting the activation of NF-\u03baB and production of RANKL: its efficacy, radiographic changes, safety and predictors over two years' treatment for Japanese rheumatoid arthritis patients","volume":"29","author":"Ishikawa","year":"2019","journal-title":"Mod. Rheumatol."},{"key":"B38","first-page":"948","article-title":"DMARDs (Focusing on iguratimod)","volume":"74","author":"Ito","year":"2016","journal-title":"Nihon Rinsho"},{"key":"B41","doi-asserted-by":"publisher","first-page":"109704","DOI":"10.1016\/j.biopha.2019.109704","article-title":"Molecular mechanisms and clinical application of Iguratimod: a review","volume":"122","author":"Jiang","year":"2020","journal-title":"Biomed. Pharmacother."},{"key":"B43","first-page":"106","article-title":"Evaluation of the clinical efficacy of methotrexate and iguratimod in the treatment of refractory rheumatoid arthritis","volume":"58","author":"Ju","year":"2020","journal-title":"China Mod. Dr."},{"key":"B44","doi-asserted-by":"publisher","first-page":"100986","DOI":"10.1016\/j.gendis.2023.04.021","article-title":"Osteoarthritis versus psoriasis arthritis: physiopathology, cellular signaling, and therapeutic strategies","volume":"11","author":"Juma","year":"2023","journal-title":"Genes Dis."},{"key":"B45","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/s11926-023-01121-w","article-title":"Multimorbidity in rheumatoid arthritis: literature review and future directions","volume":"26","author":"Katz","year":"2024","journal-title":"Curr. Rheumatol. Rep."},{"key":"B46","doi-asserted-by":"publisher","first-page":"132","DOI":"10.4078\/jrd.2022.29.3.132","article-title":"Osteoarthritis - insights from recent research","volume":"29","author":"Kim","year":"2022","journal-title":"J. Rheum. Dis."},{"key":"B47","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1097\/BOR.0000000000000923","article-title":"Inflammation in osteoarthritis: the latest progress and ongoing challenges","volume":"35","author":"Knights","year":"2023","journal-title":"Curr. Opin. Rheumatol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"153","DOI":"10.13493\/j.issn.1672-7878.2018.01-057","article-title":"Efficacy of Iguratimod and bisacodyl ryanodine in patients with refractory rheumatoid arthritis and their effects on the levels of inflammatory factors and superoxide dismutase and other indicators","volume":"15","author":"Lai","year":"2018","journal-title":"Anti-infective Pharmacol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"e567","DOI":"10.1016\/S2665-9913(23)00240-0","article-title":"Burden of rheumatoid arthritis and forecasted prevalence to 2050","volume":"5","author":"Lau","year":"2023","journal-title":"Lancet Rheumatol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1007\/s10067-019-04835-4","article-title":"Iguratimod dose dependently inhibits the expression of citrullinated proteins and peptidylarginine deiminases 2 and 4 in neutrophils from rheumatoid arthritis patients","volume":"39","author":"Li","year":"2020","journal-title":"Clin. Rheumatol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"2981","DOI":"10.11655\/zgywylc2020.18.001","article-title":"The effect of iguratimod combined with methotrexate in the treatment of rheumatoid arthritis with peripheral blood nuclear factor kappa B receptor activator ligand and bone protective factor","volume":"20","author":"Li","year":"2020","journal-title":"Chin. Med. Clin."},{"key":"B52","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41413-019-0067-6","article-title":"Iguratimod: a valuable remedy from the Asia Pacific region for ameliorating autoimmune diseases and protecting bone physiology","volume":"7","author":"Li","year":"2019","journal-title":"Bone Res."},{"key":"B53","doi-asserted-by":"publisher","first-page":"120","DOI":"10.3969\/j.issn.1000-7377.2016.01.049","article-title":"The treatment of 84 cases of senile rheumatoid arthritis with the combination of iguratimod and methotrexate","volume":"45","author":"Li","year":"2016","journal-title":"Shaanxi Med. J."},{"key":"B54","first-page":"3009","article-title":"Observation of the curative effect of iguratimod in the treatment of ankylosing spondylitis","volume":"34","author":"Li","year":"","journal-title":"J Med Theor Prac"},{"key":"B55","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.13748\/j.cnki.issn1007-7693.2014.10.029","article-title":"Recent clinical efficacy observation of Iguratimod on rheumatoid arthritis combined with chronic interstitial pneumonia","volume":"31","author":"Li","year":"2014","journal-title":"China Mod. Appl. Pharm."},{"key":"B56","doi-asserted-by":"publisher","first-page":"678864","DOI":"10.3389\/fmed.2021.678864","article-title":"Randomised, double-blind, placebo-controlled study of iguratimod in the treatment of active spondyloarthritis","volume":"8","author":"Li","year":"","journal-title":"Front. Med. (Lausanne)"},{"key":"B57","first-page":"63","article-title":"A clinical study on the treatment of early rheumatoid arthritis by iguratimod combined with methotrexate","volume":"28","author":"Li","year":"2019","journal-title":"China Pharm."},{"key":"B58","doi-asserted-by":"publisher","first-page":"6929286","DOI":"10.1155\/2019\/6929286","article-title":"Iguratimod inhibits the aggressiveness of rheumatoid fibroblast-like synoviocytes","volume":"2019","author":"Lin","year":"","journal-title":"J. Immunol. Res."},{"key":"B59","first-page":"124","article-title":"A clinical study on the treatment of rheumatoid arthritis complicated with pulmonary interstitium by iguratimod","volume":"13","author":"Lin","year":"2016","journal-title":"North. Pharm."},{"key":"B60","first-page":"9","article-title":"Preliminary observation on the treatment of ankylosing spondylitis with iguratimod","volume":"12","author":"Lin","year":"","journal-title":"J. Clin. Ration. Use"},{"key":"B61","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s10067-020-05207-z","article-title":"Molecular mechanisms and clinical studies of iguratimod for the treatment of ankylosing spondylitis","volume":"40","author":"Liu","year":"2021","journal-title":"Clin. Rheumatol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"6301","DOI":"10.2147\/JIR.S439604","article-title":"Fibroblast insights into the pathogenesis of ankylosing spondylitis","volume":"16","author":"Liu","year":"2023","journal-title":"J. Inflamm. Res."},{"key":"B63","doi-asserted-by":"publisher","first-page":"1150661","DOI":"10.3389\/fimmu.2023.1150661","article-title":"Research progress on the clinical application and mechanism of iguratimod in the treatment of autoimmune diseases and rheumatic diseases","volume":"14","author":"Long","year":"2023","journal-title":"Front. Immunol."},{"key":"B64","volume-title":"The therapeutic effect of combined application of iguratimod and methotrexate on active rheumatoid arthritis","author":"Lu","year":"2014"},{"key":"B65","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1002\/art.24643","article-title":"Multicenter, randomized, double-blind, controlled trial of treatment of active rheumatoid arthritis with T-614 compared with methotrexate","volume":"61","author":"Lu","year":"2009","journal-title":"Arthritis Rheum."},{"key":"B66","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1097\/00029330-200804010-00008","article-title":"Safety and efficacy of T-614 in the treatment of patients with active rheumatoid arthritis: a double blind, randomized, placebo-controlled and multicenter trial","volume":"121","author":"L\u00fc","year":"2008","journal-title":"Chin. Med. J. Engl."},{"key":"B67","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.13507\/j.issn.1674-3474.2019.12.024","article-title":"Clinical analysis of 46 cases of PrimarySjogren\u2019s syndrome treated by iguratimod","volume":"33","author":"Luo","year":"2019","journal-title":"Chin. J. Pract. Diagn. Ther."},{"key":"B68","doi-asserted-by":"publisher","first-page":"4969","DOI":"10.4049\/jimmunol.1300832","article-title":"A novel disease-modifying antirheumatic drug, iguratimod, ameliorates murine arthritis by blocking IL-17 signaling, distinct from methotrexate and leflunomide","volume":"191","author":"Luo","year":"2013","journal-title":"J. Immunol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1080\/03009742.2017.1390150","article-title":"Is iguratimod effective in refractory axial spondyloarthritis?","volume":"47","author":"Luo","year":"2018","journal-title":"Scand. J. Rheumatol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"45","DOI":"10.16190\/j.cnki.45-1211\/r.2019.01.011","article-title":"Efficacy and effect on serum HIF-1\u03b1 and IL-22 levels of radicicic acid polyside combined with iguratimod in the treatment of RA combined with interstitial lung disease","volume":"36","author":"Ma","year":"2019","journal-title":"J. Guangxi Med. Univ."},{"key":"B70","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1016\/S2665-9913(22)00334-4","article-title":"Role of neutrophil interleukin-23 in spondyloarthropathy spectrum disorders","volume":"5","author":"Macleod","year":"2023","journal-title":"Lancet Rheumatol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"12","DOI":"10.15887\/j.cnki.13-1389\/r.2020.21.004","article-title":"Clinical efficacy of iguratimod in the treatment of inflammatory myopathy complicated with interstitial pneumonia","volume":"13","author":"Man","year":"2020","journal-title":"J. Clin. Ration. Med."},{"key":"B72","doi-asserted-by":"publisher","first-page":"103409","DOI":"10.1016\/j.autrev.2023.103409","article-title":"Increased incidence of rheumatoid arthritis after COVID-19","volume":"22","author":"Mar\u00edn","year":"2023","journal-title":"Autoimmun. Rev."},{"key":"B73","first-page":"137","article-title":"The effect of methotrexate combined with iguratimod in the treatment of refractory rheumatoid arthritis","volume":"13","author":"Meng","year":"","journal-title":"China Med. Her."},{"key":"B74","first-page":"148","article-title":"Iguratimod combined with methotrexate on angiogenesis-related cytokines in patients with refractory rheumatoid arthritis the influence of","volume":"35","author":"Meng","year":"","journal-title":"Med. Her."},{"key":"B75","first-page":"40","article-title":"Short-term clinical efficacy of methotrexate combined with Iguratimod on refractory rheumatoid arthritis","volume":"28","author":"Meng","year":"2015","journal-title":"Chin. J. Clin. Res."},{"key":"B76","doi-asserted-by":"publisher","first-page":"153","DOI":"10.3870\/j.issn.1004-0781.2016.02.011","article-title":"Effect of Iguratimod combined with methotrexate on angiogenesis-related cytokines in patients with refractory rheumatoid arthritis","author":"Meng","year":"","journal-title":"Med. Her."},{"key":"B77","first-page":"1098","article-title":"Clinical study on the treatment of senile rheumatoid arthritis with Iguratimod tablets combined with methotrexate tablets","volume":"33","author":"Meng","year":"2017","journal-title":"Chin. J. Clin. Pharmacol."},{"key":"B78","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1007\/s40520-023-02432-9","article-title":"Chronic arthritides and bone structure: focus on rheumatoid arthritis-an update","volume":"35","author":"Messina","year":"2023","journal-title":"Aging Clin. Exp. Res."},{"key":"B79","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1097\/BOR.0000000000000985","article-title":"Epidemiology of osteoarthritis: literature update 2022-2023","volume":"36","author":"Minnig","year":"2024","journal-title":"Curr. Opin. Rheumatol."},{"key":"B80","doi-asserted-by":"publisher","first-page":"117026","DOI":"10.1016\/j.bone.2024.117026","article-title":"Iguratimod suppresses sclerostin and receptor activator of NF-\u03baB ligand production via the extracellular signal-regulated kinase\/early growth response protein 1\/tumor necrosis factor alpha pathway in osteocytes and ameliorates disuse osteoporosis in mice","volume":"181","author":"Miura","year":"2024","journal-title":"Bone"},{"key":"B81","doi-asserted-by":"publisher","first-page":"156","DOI":"10.16121\/j.cnki.cn45-1347\/r.2015.02.06","article-title":"Clinical study on the treatment of active rheumatoid arthritis with Iguratimod combined with methotrexate","volume":"10","author":"Mo","year":"2015","journal-title":"Intern. Med."},{"key":"B82","first-page":"40","article-title":"A randomized controlled trial of methotrexate combined with iguratimod in the treatment of active rheumatoid arthritis","volume":"52","author":"Mo","year":"2018","journal-title":"J. Fujian Med. Univ."},{"key":"B83","doi-asserted-by":"publisher","first-page":"e51416","DOI":"10.7759\/cureus.51416","article-title":"Navigating pain in Rheumatology: a physiotherapy-centric review on non-pharmacological pain management strategies","volume":"15","author":"Mohapatra","year":"2023","journal-title":"Cureus"},{"key":"B84","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s12325-023-02732-6","article-title":"Safety of upadacitinib in immune-mediated inflammatory diseases: systematic literature review of indirect and direct treatment comparisons of randomized controlled trials","volume":"41","author":"Mysler","year":"2024","journal-title":"Adv. Ther."},{"key":"B85","doi-asserted-by":"publisher","first-page":"457","DOI":"10.3390\/life11050457","article-title":"Iguratimod: novel molecular insights and a new csDMARD for rheumatoid arthritis, from Japan to the World","volume":"11","author":"Nozaki","year":"2021","journal-title":"Life (Basel)"},{"key":"B86","doi-asserted-by":"publisher","first-page":"534","DOI":"10.3109\/14397595.2014.998361","article-title":"Efficacy at 52 weeks of daily clinical use of iguratimod in patients with rheumatoid arthritis","volume":"25","author":"Okamura","year":"2015","journal-title":"Mod. Rheumatol."},{"key":"B87","doi-asserted-by":"publisher","first-page":"538","DOI":"10.3969\/j.issn.1672-3619.2020.04.027","article-title":"Curative effect of iguratimod combined with etanercept on ankylosing spondylitis","volume":"20","author":"Pang","year":"2020","journal-title":"J. Trop. Med."},{"key":"B88","doi-asserted-by":"publisher","first-page":"116551","DOI":"10.1016\/j.biopha.2024.116551","article-title":"Iguratimod inhibits protein citrullination and inflammation by downregulating NBCe2 in patients with rheumatoid arthritis","volume":"174","author":"Peng","year":"2024","journal-title":"Biomed. Pharmacother."},{"key":"B89","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.joca.2023.11.012","article-title":"Osteoarthritis year in review 2023: epidemiology and therapy","volume":"32","author":"Perruccio","year":"2024","journal-title":"Osteoarthr. Cartil."},{"key":"B90","first-page":"217","article-title":"Study on the efficacy and safety of methotrexate and isilamod in the treatment of rheumatoid arthritis","volume":"36","author":"Qi","year":"2019","journal-title":"Chin. J. Drug Eval."},{"key":"B91","doi-asserted-by":"publisher","first-page":"41","DOI":"10.15912\/j.cnki.gocm.2014.29.027","article-title":"Observation on the clinical efficacy of Iguratimod in the treatment of rheumatoid arthritis","volume":"12","author":"Rao","year":"2014","journal-title":"China Med. Guide"},{"key":"B92","doi-asserted-by":"publisher","first-page":"4530","DOI":"10.6039\/j.issn.1001-0408.2017.32.18","article-title":"Clinical observation of Iguratimod combined with methotrexate in the treatment of rheumatoid arthritis","volume":"28","author":"Ren","year":"2017","journal-title":"China Pharm."},{"key":"B93","doi-asserted-by":"publisher","first-page":"1303640","DOI":"10.3389\/fimmu.2023.1303640","article-title":"Regulatory T cells in spondyloarthropathies: genetic evidence, functional role, and therapeutic possibilities","volume":"14","author":"Rodolfi","year":"2024","journal-title":"Front. Immunol."},{"key":"B94","doi-asserted-by":"publisher","first-page":"103423","DOI":"10.1016\/j.autrev.2023.103423","article-title":"Residual pain in rheumatoid arthritis: is it a real problem?","volume":"22","author":"Sarzi-Puttini","year":"2023","journal-title":"Autoimmun. Rev."},{"key":"B95","doi-asserted-by":"publisher","first-page":"101836","DOI":"10.1016\/j.berh.2023.101836","article-title":"The burden of osteoarthritis: is it a rising problem?","volume":"37","author":"Scheuing","year":"2023","journal-title":"Best. Pract. Res. Clin. Rheumatol."},{"key":"B96","doi-asserted-by":"publisher","first-page":"593","DOI":"10.3969\/j.issn.1006-2238.2019.6.004","article-title":"Efficacy of iguratimod tablet monotherapy in the treatment of active rheumatoid arthritis and its effect on bone metabolism","volume":"54","author":"Shang","year":"2019","journal-title":"Jiangxi Med."},{"key":"B97","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13075-024-03268-y","article-title":"Correction: iguratimod attenuated fbrosis in systemic sclerosis via targeting early growth response 1 expression","volume":"26","author":"Shen","year":"2024","journal-title":"Arthritis Res. Ther."},{"key":"B98","first-page":"31","article-title":"Analysis of the efficacy of iguratimod combined with disease-improving antirheumatic drugs in the treatment of rheumatoid arthritis combined with osteoporosis","volume":"21","author":"Shi","year":"2023","journal-title":"J. Clin. Pharmacother."},{"key":"B99","first-page":"5","article-title":"Efficacy and safety of methotrexate combined with iguratimod in the treatment of active rheumatoid arthritis","volume-title":"J. Nanjing Med. Univ.","author":"Shi","year":"2015"},{"key":"B100","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1007\/s10067-020-04986-9","article-title":"Relative efficacy and safety of iguratimod monotherapy for the treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis","volume":"39","author":"Shrestha","year":"2020","journal-title":"Clin. Rheumatol."},{"key":"B101","doi-asserted-by":"publisher","first-page":"2256418","DOI":"10.1080\/0886022X.2023.2256418","article-title":"Efficacy of iguratimod on mineral and bone disorders after kidney transplantation: a preliminary study","volume":"45","author":"Sun","year":"2023","journal-title":"Ren. Fail"},{"key":"B102","first-page":"41","article-title":"Clinical efficacy of Iguratimod combined with methotrexate in the treatment of rheumatoid arthritis and its effect on bone metabolism in patients","volume":"29","author":"Sun","year":"2022","journal-title":"Clin. Med. Eng."},{"key":"B103","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1080\/14397595.2018.1510879","article-title":"The three-year efficacy of iguratimod in clinical daily practice in patients with rheumatoid arthritis","volume":"29","author":"Suto","year":"2019","journal-title":"Mod. Rheumatol."},{"key":"B104","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1080\/08820139.2023.2293095","article-title":"Role of MicroRNAs in inflammatory joint diseases: a review","volume":"53","author":"Syed","year":"2023","journal-title":"Immunol. Invest."},{"key":"B105","doi-asserted-by":"publisher","first-page":"e351","DOI":"10.1016\/S2665-9913(23)00094-2","article-title":"Pain in the joints and beyond; the challenge of rheumatoid arthritis","volume":"5","author":"Taylor","year":"2023","journal-title":"Lancet Rheumatol."},{"key":"B106","first-page":"391","article-title":"The effect of Iguratimod combined with methotrexate on serum M-CSF, IL-6, IL-8 and bone metabolism in patients with rheumatoid arthritis","volume":"28","author":"Tian","year":"2017","journal-title":"Hainan Med."},{"key":"B107","doi-asserted-by":"publisher","first-page":"148","DOI":"10.3760\/cma.j.issn.1007-7480.2020.03.002","article-title":"Efficacy and safety of iguratimod or leflunomide combined with methotrexate in the treatment of active rheumatoid arthritis Sexual comparison: a multicenter randomized double-blind double-simulation controlled clinical study","volume":"24","author":"Tian","year":"2020","journal-title":"Chin. J. Rheumatology"},{"key":"B108","doi-asserted-by":"publisher","first-page":"101897","DOI":"10.1016\/j.berh.2023.101897","article-title":"Pathophysiology and immunolgical basis of axial spondyloarthritis","volume":"37","author":"van de Sande","year":"2023","journal-title":"Best. Pract. Res. Clin. Rheumatol."},{"key":"B109","doi-asserted-by":"publisher","first-page":"404","DOI":"10.31138\/mjr.301223.eaf","article-title":"Epidemiology and risk factors for rheumatoid arthritis development","volume":"34","author":"Venetsanopoulou","year":"2023","journal-title":"Mediterr. J. Rheumatol."},{"key":"B110","first-page":"231","article-title":"Clinical study on the treatment of rheumatoid arthritis with methotrexate tablets combined with Iguratimod tablets","volume":"35","author":"Wang","year":"2019","journal-title":"Chin. J. Clin. Pharmacol."},{"key":"B111","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1007\/s10067-017-3668-8","article-title":"Effects of iguratimod on the levels of circulating regulators of bone remodeling and bone remodeling markers in patients with rheumatoid arthritis","volume":"36","author":"Wang","year":"2017","journal-title":"Clin. Rheumatol."},{"key":"B112","doi-asserted-by":"publisher","first-page":"75","DOI":"10.16462\/j.cnki.zhjbkz.2018.01.017","article-title":"Clinical study of effectiveness and safety of iguratimod in treating primary sjogren\u2019s syndrome","volume":"22","author":"Wang","year":"2018","journal-title":"Chin. J. Dis. Control Prev."},{"key":"B113","volume-title":"Study on the effect of iguratimod on bone metabolism in patients with rheumatoid arthritis[D]","author":"Wang","year":"2017"},{"key":"B114","doi-asserted-by":"publisher","first-page":"292","DOI":"10.3969\/j.issn.1000-7377.2015.03.011","article-title":"Experimental study on the in vitro intervention of Iguratimod on synovial cells in rheumatoid arthritis","author":"Wang","year":"2015","journal-title":"Shaanxi Med. J."},{"key":"B115","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/s41413-023-00301-9","article-title":"Risk of metabolic abnormalities in osteoarthritis: a new perspective to understand its pathological mechanisms","volume":"11","author":"Wei","year":"2023","journal-title":"Bone Res."},{"key":"B40","first-page":"183","article-title":"Repairing effect and safety analysis of Iguratimod combined with methotrexate and tretinoin on articular chondrocyte damage in rheumatoid arthritis","volume":"26","author":"Wu","year":"2022","journal-title":"Anhui Med."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.12092\/j.issn.1009-2501.2018.10.008","article-title":"Systematic evaluation and meta-analysis of the efficacy and safety of iguratimod combined with methotrexate in the treatment of rheumatoid arthritis","volume":"23","author":"Wu","year":"2018","journal-title":"Chin. Clin. Pharmacol. Ther."},{"key":"B116","first-page":"76","article-title":"Observation on the effects of Iguratimod and Tripterygium Glycosides in the treatment of rheumatoid arthritis","volume":"20","author":"Xia","year":"2020","journal-title":"Pract. Integr. Traditional Chin. West. Med."},{"key":"B117","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1007\/s00393-015-1641-y","article-title":"Iguratimod in combination with methotrexate in active rheumatoid arthritis: therapeutic effects","volume":"75","author":"Xia","year":"2016","journal-title":"Z Rheumatol."},{"key":"B118","first-page":"831","article-title":"The effect of Iguratimod combined with MTX on IL-1, serum TNF-\u03b1 and VEGF levels in patients with refractory rheumatoid arthritis","volume":"42","author":"Xie","year":"2018","journal-title":"Guizhou Med."},{"key":"B119","doi-asserted-by":"publisher","first-page":"73","DOI":"10.3389\/fphar.2020.00073","article-title":"Iguratimod as a new drug for rheumatoid arthritis: current landscape","volume":"11","author":"Xie","year":"2020","journal-title":"Front. Pharmacol."},{"key":"B120","first-page":"93","article-title":"The clinical efficacy of methotrexate combined with iguratimod on active rheumatoid arthritis","volume":"29","author":"Xiong","year":"2020","journal-title":"Henan Med. Res."},{"key":"B125","doi-asserted-by":"publisher","first-page":"833","DOI":"10.3969\/j.issn.1001-9057.2015.12.014","article-title":"Study on the effect of iguratimod combined with methotrexate treatment on anti-cyclic guanidine peptide antibodies and other indicators in patients with rheumatoid arthritis","volume":"32","author":"Xiong","year":"2015","journal-title":"J. Clin. Intern. Med."},{"key":"B2","first-page":"120","article-title":"Clinical study of methotrexate combined with iguratimod in the treatment of rheumatoid arthritis","volume":"19","author":"Xu","year":"2015","journal-title":"J. Clin. Med. Pract."},{"key":"B121","first-page":"POS0399","article-title":"The ion channel TRPV4 participates in the cartilage protection of Iguratimod on knee osteoarthritis","author":"Xu","year":"2023","journal-title":"EULAR"},{"key":"B122","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.lfs.2019.05.003","article-title":"Excessive mechanical stress induces chondrocyte apoptosis through TRPV4 in an anterior cruciate ligament-transected rat osteoarthritis model","volume":"228","author":"Xu","year":"","journal-title":"Life Sci."},{"key":"B123","first-page":"915","article-title":"Study on the efficacy and safety of iguratimod in the treatment of ankylosing spondylitis","volume":"50","author":"Xu","year":"","journal-title":"New Med."},{"key":"B124","first-page":"47","article-title":"Clinical observation on the treatment of rheumatoid arthritis with Iguratimod combined with methotrexate","volume":"15","author":"Xu","year":"2017","journal-title":"Guide Chin. Med."},{"key":"B126","doi-asserted-by":"publisher","first-page":"421","DOI":"10.19842\/j.cnki.issn.0253-9934.2021.06.013","article-title":"Observation on the clinical efficacy of iguratimod in the treatment of axial spondyloarthritis","volume":"44","author":"Xu","year":"2021","journal-title":"Shanghai Med. J."},{"key":"B127","first-page":"2055","article-title":"Evaluation of the efficacy of high-frequency ultrasound in the treatment of rheumatoid arthritis with Iguratimod","volume":"28","author":"Wang","year":"2022","journal-title":"Med. Rev."},{"key":"B128","doi-asserted-by":"publisher","first-page":"369","DOI":"10.13463\/j.cnki.cczyy.2018.02.054","article-title":"Effect of Iguratimod combined with methotrexate on serum-related cytokines and bone metabolism in patients with rheumatoid arthritis","volume":"34","author":"Yan","year":"2018","journal-title":"J. Changchun Univ. Traditional Chin. Med."},{"key":"B129","first-page":"114","article-title":"Observation on the efficacy of methotrexate combined with iguratimod in the treatment of rheumatoid arthritis","volume":"34","author":"Yi","year":"2022","journal-title":"Mod. Pract. Med."},{"key":"B130","doi-asserted-by":"publisher","first-page":"169","DOI":"10.3109\/14397595.2015.1069475","article-title":"Disease activity early in treatment as a predictor of future low disease activity in RA patients treated with iguratimod","volume":"26","author":"Yoshioka","year":"2016","journal-title":"Mod. Rheumatol."},{"key":"B131","first-page":"163","article-title":"Efficacy of iguratimod combined with methotrexate in the treatment of refractory ankylosing spondylitis and its effect on serum SOD and CTX-I levels in patients","volume":"29","author":"Yuan","year":"2020","journal-title":"J. Pharm. Epidemiol."},{"key":"B132","first-page":"118","article-title":"Observation on the efficacy of iguratimod in the treatment of ankylosing spondylitis","volume":"27","author":"Zeng","year":"2016","journal-title":"Hainan Med."},{"key":"B35","doi-asserted-by":"publisher","first-page":"216","DOI":"10.3760\/cma.j.issn.1674?1927.2019.02.016","article-title":"A preliminary study on the efficacy and mechanism of action of Iguratimod on knee osteoarthritis","author":"Zeng","year":"2019","journal-title":"Chin. J. Biomed. Eng."},{"key":"B133","doi-asserted-by":"publisher","first-page":"1189142","DOI":"10.3389\/fphar.2023.1189142","article-title":"Efficacy and safety of iguratimod in the treatment of rheumatic and autoimmune diseases: a meta-analysis and systematic review of 84 randomized controlled trials","volume":"14","author":"Zeng","year":"2023","journal-title":"Front. Pharmacol."},{"key":"B134","doi-asserted-by":"publisher","first-page":"924730","DOI":"10.3389\/fimmu.2022.924730","article-title":"A systematic review and meta-analysis of 19 randomized controlled trials of iguratimod combined with other therapies for sjogren's syndrome","volume":"13","author":"Zeng","year":"","journal-title":"Front. Immunol."},{"key":"B135","doi-asserted-by":"publisher","first-page":"780154","DOI":"10.3389\/fphar.2021.780154","article-title":"The effect and safety of iguratimod combined with methotrexate on rheumatoid arthritis: a systematic review and meta-analysis based on a randomized controlled trial","volume":"12","author":"Zeng","year":"","journal-title":"Front. Pharmacol."},{"key":"B136","doi-asserted-by":"publisher","first-page":"114","DOI":"10.3969\/j.issn.1006-1959.2022.15.026","article-title":"Efficacy of Iguratimod combined with celecoxib in the treatment of ankylosing spondylitis","volume":"35","author":"Zhang","year":"2022","journal-title":"Med. Inf."},{"key":"B137","doi-asserted-by":"publisher","first-page":"404","DOI":"10.14009\/j.issn.1672-2124.2023.04.004","article-title":"Clinical efficacy of Iguratimod combined with glucosamine sulfate in the treatment of osteoarthritis and its effect on patients' cartilage metabolism","volume":"23","author":"Zhang","year":"2023","journal-title":"China Hosp. Drug Eval. Analysis"},{"key":"B138","first-page":"44","article-title":"The clinical effect of Iguratimod combined with methotrexate in the treatment of rheumatoid arthritis","volume":"3","author":"Zhao","year":"2018","journal-title":"Clin. Med. Res. Pract."},{"key":"B139","first-page":"2353","article-title":"Analysis of efficacy and safety of treatment of active rheumatoid arthritis with iguratimod and methotrexate","volume":"28","author":"Zhao","year":"2017","journal-title":"Biomed. Res."},{"key":"B140","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1111\/1756-185X.13463","article-title":"Iguratimod ameliorates bleomycin-induced alveolar inflammation and pulmonary fibrosis in mice by suppressing expression of matrix metalloproteinase-9","volume":"22","author":"Zhao","year":"2019","journal-title":"Int. J. Rheum. Dis."},{"key":"B141","first-page":"450","article-title":"Clinical study of Iguratimod in the treatment of active rheumatoid arthritis","volume":"39","author":"Zhao","year":"2016","journal-title":"Chin. J. Postgraduates Med."},{"key":"B142","doi-asserted-by":"publisher","first-page":"265","DOI":"10.7150\/thno.90940","article-title":"Lymphatic vessels: roles and potential therapeutic intervention in rheumatoid arthritis and osteoarthritis","volume":"14","author":"Zhou","year":"2024","journal-title":"Theranostics"},{"key":"B143","first-page":"93","article-title":"A study on the clinical efficacy of iguratimod on rheumatoid arthritis and the regulation of T helper cell subsets","volume":"20","author":"Zhu","year":"2016","journal-title":"Chin. Rheumatism J. Sci."},{"key":"B144","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.19723\/j.issn.1671-167X.2023.06.009","article-title":"Effectiveness of tofacitinib combined with iguratimod in the treatment of difficult-to-treat moderate-to-severe rheumatoid arthritis","volume":"55","author":"Zou","year":"2023","journal-title":"Beijing Da Xue Xue Bao Yi Xue Ban."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1440584\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T03:20:27Z","timestamp":1728530427000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1440584\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,10]]},"references-count":144,"alternative-id":["10.3389\/fphar.2024.1440584"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1440584","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,10]]},"article-number":"1440584"}}